A Discussion With Experts on the Evolving Therapeutic Landscape in T-Cell Lymphomas: Focus on EZH1/2 Inhibitors

Download All
Get up to date on the optimal use of EZH1/2 inhibitors in PTCL with this expert-authored commentary plus downloadable slides and on-demand webcast from a live CCO symposium at ASCO 2022.
Steven M. Horwitz, MD
Program Director
Pamela B. Allen, MD
Steven M. Horwitz, MD
Pierluigi Porcu, MD

Downloadable Slidesets

Download these slides from a live expert-led satellite symposium reviewing the latest advances in peripheral T-Cell lymphomas.

Steven M. Horwitz, MD
Program Director
Pamela B. Allen, MD
Released: June 2, 2022

Download these slides from a live expert-led satellite symposium reviewing the mechanisms of Anti-EZH1 and EZH2 therapies in PTCL.

Steven M. Horwitz, MD
Program Director
Pierluigi Porcu, MD
Released: June 2, 2022

Download these slides from a live expert-led satellite symposium reviewing the clinical trial efficacy and safety of Anti-EZH1 and EZH2 therapies in PTCL.

Steven M. Horwitz, MD Released: June 3, 2022

On-Demand Webcast

In this on-demand webcast from a live symposium, Steven M. Horwitz, MD; Pamela B. Allen, MD; and Pierluigi Porcu, MD discuss the rationale, evidence, and strategies for using EZH1/2 inhibitors in patients with peripheral T-cell lymphomas.

Steven M. Horwitz, MD
Program Director
Pamela B. Allen, MD Pierluigi Porcu, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: June 8, 2022 Expired: June 7, 2023
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Daiichi Sankyo, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings